Skip to main content

Table 4 Progesterone immunoassay cross-reactivity

From: Cross-reactivity of steroid hormone immunoassays: clinical significance and two-dimensional molecular similarity prediction

Compound Plasma/serum concentrations Cross-reactivity in Roche assay Likelihood of clinically significant cross-reactivity
Progesterone • 0.2 – 1.4 ng/mL (males) [44] 100% High (assay target)
• Up to 27 ng/mL (women) [44]
5β-Dihydroprogesterone Up to 0.8 ng/mL in adults [45] 18.2% Possible significant contribution for individuals with progesterone concentrations on the lower end of reference interval
17-Hydroxyprogesterone • 0.08 – 2.0 ng/mL (pediatric controls) [22] 1.2% Low, except in patients with 21-hydroxylase deficiency
• Up to 1,005 ng/mL (21-hydroxylase deficiency) [22]
Pregnanolone Up to 17 ng/mL in women [33] 0.90% Low
Allopregnanolone Up to 29 ng/mL in women [33] 0.82% Low
Medroxyprogesterone Up to 100 ng/mL following dosing in women [46] 0.67% Possible significant contribution for individuals with progesterone concentrations on the lower end of reference interval
Corticosterone • 0.18 – 2.0 ng/mL (18 years and younger) [24] 0.54% Low
• 0.53 – 1.6 ng/mL (<18 years) [24]
11-Deoxycortisol • 0.17 – 1.8 ng/mL (pediatric controls) [22] 0.39% Low, except in patients following metyrapone challenge or who have 11β-hydroxylase deficiency
• Up to 63 ng/mL (11β-hydroxylase deficiency) [22]
• Up to 250 ng/mL (metyrapone challenge) [25]
Nandrolone Up to 5.16 ng/mL in men following intramuscular injection [47] 0.17% Low
Pregnenolone Up to 3.27 ng/mL in women [33] 0.12% Low
Exemestane Up to 441 ng/mL in post-menopausal women [48] 0.09% Possible significant effect if progesterone measured near peak of exemestane plasma concentration
Androstenedione • Up to 0.86 ng/mL before onset of puberty [30] 0.09% Low
  • Up to 3.2 ng/mL in 21-hydroxylase deficiency [30]